Thresholds for the cost–effectiveness of interventions: alternative approaches

Abstract Many countries use the cost–effectiveness thresholds recommended by the World Health Organization’s Choosing Interventions that are Cost–Effective project (WHO-CHOICE) when evaluating health interventions. This project sets the threshold for cost–effectiveness as the cost of the intervention per disability-adjusted life-year (DALY) averted less than three times the country’s annual gross domestic product (GDP) per capita. Highly cost–effective interventions are defined as meeting a threshold per DALY averted of once the annual GDP per capita. We argue that reliance on these thresholds reduces the value of cost–effectiveness analyses and makes such analyses too blunt to be useful for most decision-making in the field of public health. Use of these thresholds has little theoretical justification, skirts the difficult but necessary ranking of the relative values of locally-applicable interventions and omits any consideration of what is truly affordable. The WHO-CHOICE thresholds set such a low bar for cost–effectiveness that very few interventions with evidence of efficacy can be ruled out. The thresholds have little value in assessing the trade-offs that decision-makers must confront. We present alternative approaches for applying cost–effectiveness criteria to choices in the allocation of health-care resources.

[1]  P. Moszynski Global Fund suspends new projects until 2014 because of lack of funding , 2011, BMJ : British Medical Journal.

[2]  A Gafni,et al.  Opportunity costs and uncertainty in the economic evaluation of health care interventions. , 2002, Health economics.

[3]  A. Garber,et al.  Economic foundations of cost-effectiveness analysis. , 1997, Journal of health economics.

[4]  Sarah C Leeper,et al.  United States global health policy: HIV/AIDS, maternal and child health, and The President's Emergency Plan for AIDS Relief (PEPFAR) , 2010, AIDS.

[5]  K. Kawai,et al.  Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model , 2012, BMC Infectious Diseases.

[6]  Karla Hemming,et al.  Sample size calculations for cluster randomised controlled trials with a fixed number of clusters , 2011, BMC medical research methodology.

[7]  Anthony J. Culyer,et al.  Cost-effectiveness Analysis Registry , 2014 .

[8]  M Johannesson,et al.  Some reflections on cost-effectiveness analysis. , 1998, Health economics.

[9]  J. Stringer,et al.  Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia , 2012, PloS one.

[10]  D M Eddy,et al.  Clinical decision making: from theory to practice. Cost-effectiveness analysis. Is it up to the task? , 1992, JAMA.

[11]  Martin J. Aryee,et al.  Diarrhea incidence in low- and middle-income countries in 1990 and 2010: a systematic review , 2012, BMC Public Health.

[12]  J. Mauskopf,et al.  Cost-effectiveness league tables: valuable guidance for decision makers? , 2003, PharmacoEconomics.

[13]  R. Robinson Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .

[14]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  C. I. Jones,et al.  The Value of Life and the Rise in Health Spending , 2004 .

[16]  J. Ioannidis,et al.  Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment , 2013, BMJ : British Medical Journal.

[17]  T. Edejer,et al.  Generalized cost-effectiveness analysis for national-level priority-setting in the health sector , 2003, Cost effectiveness and resource allocation : C/E.

[18]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[19]  M. Drummond,et al.  Cost-effectiveness league tables: more harm than good? , 1993, Social science & medicine.

[20]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.

[21]  T. Clasen,et al.  Cost of Community Integrated Prevention Campaign for Malaria, HIV, and Diarrhea in Rural Kenya , 2011, BMC health services research.

[22]  Kristian Thorlund,et al.  Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? , 2009, International journal of epidemiology.

[23]  L. Weinehall,et al.  Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease? , 1999, Health policy.

[24]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  L. Newman,et al.  The Cost and Cost-Effectiveness of Scaling up Screening and Treatment of Syphilis in Pregnancy: A Model , 2014, PloS one.

[26]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, BJOG : an international journal of obstetrics and gynaecology.

[27]  T. Clasen,et al.  Cost-effectiveness of water quality interventions for preventing diarrhoeal disease in developing countries. , 2007, Journal of water and health.

[28]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[29]  A. Galvani,et al.  Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania. , 2009, Vaccine.

[30]  N. Bristol Slow going for the global health initiative. , 2011, Health affairs.

[31]  C. Roelofs Prevention effectiveness: A guide to decision analysis and economic evaluation , 1997 .

[32]  P. Taylor Clinical Decision Making: From Theory to Practice , 1996 .

[33]  J. Lave,et al.  Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource Allocation , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  David O. Meltzer,et al.  Editorial: Some reflections on cost‐effectiveness analysis , 1998 .

[35]  A. Gulland Global Fund needs $15bn to fight HIV, tuberculosis, and malaria , 2013, BMJ : British Medical Journal.

[36]  Richard J. Zeckhauser,et al.  Critical ratios and efficient allocation , 1973 .

[37]  P. Moszynski Progress in global access to medicines threatened by funding shortfalls, warns charity , 2011, BMJ : British Medical Journal.

[38]  Guilbert Jj The world health report 2002 - reducing risks, promoting healthy life. , 2003 .

[39]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[40]  R. Baltussen,et al.  Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries , 2005, BMJ : British Medical Journal.

[41]  A. Boardman,et al.  Cost-Benefit Analysis: Concepts and Practice , 1996 .